Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 3 3 Phase 2/3 1 Phase 1/2 1

Status

Completed 4 Unknown 1 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lung Neoplasms 1

Interventions

Cyclophosphamide 37 Gemcitabine 31 Paclitaxel 27 Cisplatin 27 Carboplatin 27 Capecitabine 27 camrelizumab 24 Nivolumab 23 apatinib 22 Oxaliplatin 21 fludarabine 20 Radiotherapy 20 toripalimab 17 Immunotherapy, Adoptive 17 Drug Therapy 17 pembrolizumab 16 Docetaxel 16 Dexamethasone 15 Bevacizumab 15 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14 Injections 14 tislelizumab 13 Temozolomide 13 Rituximab 13 Cetuximab 13 Irinotecan 12 130-nm albumin-bound paclitaxel 11 anlotinib 10 Fluorouracil 10 Trastuzumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × Crizotinib × Clear all

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡